
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is focused on developing lanifibranor, a candidate therapy for non-alcoholic steatohepatitis (NASH), with promising clinical results indicating significant efficacy in improving both fibrosis and metabolic markers in patients. The company's strong financial outlook is supported by research partnerships with AbbVie and BI, which contribute to its revenue stream and validate its research efforts. Additionally, positive clinical trial outcomes suggest that lanifibranor could be a leading treatment option in the NASH landscape, potentially enhancing market penetration and increasing adoption in clinical settings.
Bears say
Inventiva SA, a biopharmaceutical company focused on developing therapies for NASH and other conditions, reported a significant net loss of €175.9 million, translating to €1.62 per share, highlighting financial challenges amid ongoing clinical developments. The company's primary clinical candidate, lanifibranor, is in Phase III trials, with any safety or efficacy issues potentially having detrimental effects on stock performance, particularly in a competitive landscape where existing treatments have been characterized as underwhelming. Additional risks include possible clinical trial failures, delays in regulatory timelines, and difficulties in securing financing, which together contribute to a cautious outlook on the company's future financial stability.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares